First-in-human study of blood amyloid β removal from early Alzheimer's disease patients with normal kidney function

Midori Hasegawa; Nobuya Kitaguchi; Hajime Takechi; Kazunori Kawaguchi; Kengo Ito; Takashi Kato; Masao Kato; Norio Nii; Sachie Yamada; Atsushi Ohashi; Shigehisa Koide; Hiroki Hayashi; Kazuo Takahashi; Daijo Inaguma; Yukio Yuzawa; Naotake Tsuboi

doi:10.1111/1744-9987.13827

First-in-human study of blood amyloid β removal from early Alzheimer's disease patients with normal kidney function

Midori Hasegawa, Nobuya Kitaguchi, Hajime Takechi, Kazunori Kawaguchi, Kengo Ito, Takashi Kato, Masao Kato, Norio Nii, Sachie Yamada, Atsushi Ohashi, Shigehisa Koide, Hiroki Hayashi, Kazuo Takahashi, Daijo Inaguma, Yukio Yuzawa, Naotake Tsuboi

Research output: Contribution to journal › Article › peer-review

1 Citation (Scopus)

Abstract

Introduction: Amyloid β (Aβ) is a brain protein that causes Alzheimer's disease (AD). This study aimed to verify whether hemadsorption using a hexadecyl-alkylated cellulose bead (HexDC) column removes blood Aβ and brain Aβ accumulation in mild cognitive impairment/mild AD cases with normal kidney function. Methods: Two patients with positive Aβ on brain imaging underwent HexDC hemadsorption weekly for 6 months. Results: The Aβ removal efficiency of HexDC was 87–99%. Aβ₁₋₄₀/Aβ₁₋₄₂ influx into the blood in one session was 596/56 and 489/48 ng for Case A and Case B, respectively. Although brain Aβ accumulation did not clearly change after 6 months of hemadsorption, cognitive functions measured by the two tests were maintained or slightly improved. Conclusion: Blood Aβ removal was performed in two early AD patients with normal kidney function without adverse events, and it slightly improved or maintained cognitive function.

Original language	English
Pages (from-to)	529-536
Number of pages	8
Journal	Therapeutic Apheresis and Dialysis
Volume	26
Issue number	3
DOIs	https://doi.org/10.1111/1744-9987.13827
Publication status	Published - 06-2022

All Science Journal Classification (ASJC) codes

Hematology
Nephrology

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1111/1744-9987.13827

Cite this

Hasegawa, M., Kitaguchi, N., Takechi, H., Kawaguchi, K., Ito, K., Kato, T., Kato, M., Nii, N., Yamada, S., Ohashi, A., Koide, S., Hayashi, H., Takahashi, K., Inaguma, D., Yuzawa, Y., & Tsuboi, N. (2022). First-in-human study of blood amyloid β removal from early Alzheimer's disease patients with normal kidney function. Therapeutic Apheresis and Dialysis, 26(3), 529-536. https://doi.org/10.1111/1744-9987.13827

@article{4a09b5f35477410c959d16f7ece1881e,

title = "First-in-human study of blood amyloid β removal from early Alzheimer's disease patients with normal kidney function",

abstract = "Introduction: Amyloid β (Aβ) is a brain protein that causes Alzheimer's disease (AD). This study aimed to verify whether hemadsorption using a hexadecyl-alkylated cellulose bead (HexDC) column removes blood Aβ and brain Aβ accumulation in mild cognitive impairment/mild AD cases with normal kidney function. Methods: Two patients with positive Aβ on brain imaging underwent HexDC hemadsorption weekly for 6 months. Results: The Aβ removal efficiency of HexDC was 87–99%. Aβ1−40/Aβ1−42 influx into the blood in one session was 596/56 and 489/48 ng for Case A and Case B, respectively. Although brain Aβ accumulation did not clearly change after 6 months of hemadsorption, cognitive functions measured by the two tests were maintained or slightly improved. Conclusion: Blood Aβ removal was performed in two early AD patients with normal kidney function without adverse events, and it slightly improved or maintained cognitive function.",

author = "Midori Hasegawa and Nobuya Kitaguchi and Hajime Takechi and Kazunori Kawaguchi and Kengo Ito and Takashi Kato and Masao Kato and Norio Nii and Sachie Yamada and Atsushi Ohashi and Shigehisa Koide and Hiroki Hayashi and Kazuo Takahashi and Daijo Inaguma and Yukio Yuzawa and Naotake Tsuboi",

note = "Publisher Copyright: {\textcopyright} 2022 International Society for Apheresis and Japanese Society for Apheresis.",

year = "2022",

month = jun,

doi = "10.1111/1744-9987.13827",

language = "English",

volume = "26",

pages = "529--536",

journal = "Therapeutic Apheresis and Dialysis",

issn = "1744-9979",

publisher = "Wiley-Blackwell",

number = "3",

}

Hasegawa, M, Kitaguchi, N, Takechi, H , Kawaguchi, K, Ito, K, Kato, T, Kato, M, Nii, N, Yamada, S, Ohashi, A , Koide, S , Hayashi, H , Takahashi, K , Inaguma, D , Yuzawa, Y & Tsuboi, N 2022, 'First-in-human study of blood amyloid β removal from early Alzheimer's disease patients with normal kidney function', Therapeutic Apheresis and Dialysis, vol. 26, no. 3, pp. 529-536. https://doi.org/10.1111/1744-9987.13827

TY - JOUR

T1 - First-in-human study of blood amyloid β removal from early Alzheimer's disease patients with normal kidney function

AU - Hasegawa, Midori

AU - Kitaguchi, Nobuya

AU - Takechi, Hajime

AU - Kawaguchi, Kazunori

AU - Ito, Kengo

AU - Kato, Takashi

AU - Kato, Masao

AU - Nii, Norio

AU - Yamada, Sachie

AU - Ohashi, Atsushi

AU - Koide, Shigehisa

AU - Hayashi, Hiroki

AU - Takahashi, Kazuo

AU - Inaguma, Daijo

AU - Yuzawa, Yukio

AU - Tsuboi, Naotake

PY - 2022/6

Y1 - 2022/6

N2 - Introduction: Amyloid β (Aβ) is a brain protein that causes Alzheimer's disease (AD). This study aimed to verify whether hemadsorption using a hexadecyl-alkylated cellulose bead (HexDC) column removes blood Aβ and brain Aβ accumulation in mild cognitive impairment/mild AD cases with normal kidney function. Methods: Two patients with positive Aβ on brain imaging underwent HexDC hemadsorption weekly for 6 months. Results: The Aβ removal efficiency of HexDC was 87–99%. Aβ1−40/Aβ1−42 influx into the blood in one session was 596/56 and 489/48 ng for Case A and Case B, respectively. Although brain Aβ accumulation did not clearly change after 6 months of hemadsorption, cognitive functions measured by the two tests were maintained or slightly improved. Conclusion: Blood Aβ removal was performed in two early AD patients with normal kidney function without adverse events, and it slightly improved or maintained cognitive function.

AB - Introduction: Amyloid β (Aβ) is a brain protein that causes Alzheimer's disease (AD). This study aimed to verify whether hemadsorption using a hexadecyl-alkylated cellulose bead (HexDC) column removes blood Aβ and brain Aβ accumulation in mild cognitive impairment/mild AD cases with normal kidney function. Methods: Two patients with positive Aβ on brain imaging underwent HexDC hemadsorption weekly for 6 months. Results: The Aβ removal efficiency of HexDC was 87–99%. Aβ1−40/Aβ1−42 influx into the blood in one session was 596/56 and 489/48 ng for Case A and Case B, respectively. Although brain Aβ accumulation did not clearly change after 6 months of hemadsorption, cognitive functions measured by the two tests were maintained or slightly improved. Conclusion: Blood Aβ removal was performed in two early AD patients with normal kidney function without adverse events, and it slightly improved or maintained cognitive function.

UR - http://www.scopus.com/inward/record.url?scp=85126785590&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85126785590&partnerID=8YFLogxK

U2 - 10.1111/1744-9987.13827

DO - 10.1111/1744-9987.13827

M3 - Article

C2 - 35294796

AN - SCOPUS:85126785590

SN - 1744-9979

VL - 26

SP - 529

EP - 536

JO - Therapeutic Apheresis and Dialysis

JF - Therapeutic Apheresis and Dialysis

IS - 3

ER -

First-in-human study of blood amyloid β removal from early Alzheimer's disease patients with normal kidney function

Abstract

All Science Journal Classification (ASJC) codes

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this